BioSig Technologies Announce PURE EP System Pre-Clinical Data to be Presented at International Dead Sea Symposium

BioSig Technologies, Inc. (TSXV:BIO) announced that pre-clinical data, gathered during a series of studies from 2015 at the Mayo Clinic, will be presented at the 13^thInternational Dead Sea Symposium on Innovations in Cardiac Arrhythmias and Device Therapy at the David Intercontinental Convention Center in Tel Aviv, Israel.
BioSig Technologies President and CEO, Greg Cash, stated:

These important pre-clinical data characterize the PURE EP System’s ability to improve acquisition and visualization of high fidelity cardiac signals, and is an important milestone for the company. We have been very pleased with our collaboration with Dr. Samuel Asirvatham and his team and look forward to continuing this work at the Mayo Clinic.